Table 3 The association between the tumor burden and the response to anti-PD-1 monotherapy in patients with recurrent or metastatic head and neck cancer.

From: Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

 

N

Univariate analysis

Multivariate analysis

Disease control rate

Disease control rate

HR

95% CI

p-value

HR

95% CI

p-value

BNML

one

42

1.00

–

–

1.00

–

–

more

52

2.54

1.04–6.22

0.042

2.81

1.10–7.20

0.031

BSLD

 ≤ 28

33

1.00

–

–

1.00

–

–

 > 28

61

3.57

1.29–9.90

0.014

4.71

1.53–14.50

0.006

SUVmax

 ≤ 12.93

23

1.00

–

–

1.00

–

–

 > 12.93

25

4.28

1.16–16.60

0.030

18.60

1.95–178.00

0.011

  1. Adjusted by age, sex, Eastern Cooperative Oncology Group performance status.
  2. HR hazard ratio, CI confidence interval, BNML the baseline number of metastatic lesions, BSLD the baseline sum of the longest diameters of the target lesions, SUV standardized uptake value.
Back to article page